IGC Pharma (NYSE American: IGC) will present new Tau-PET biomarker research at the 2026 Global Tau Conference in Washington, D.C., May 14-15, 2026.
The study uses Shannon entropy on Tau-PET data from 931 participants to assess tau spreading patterns, cognition, and potential use in Alzheimer's monitoring and patient stratification.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IGC
-4.35%
-4.35%Session close to close
In the May 15 session, IGC declined 4.35%, reflecting a moderate negative market reaction.
This announcement spotlights IGC’s effort to build an Alzheimer’s imaging and analytics platform usi...
Analysis
This announcement spotlights IGC’s effort to build an Alzheimer’s imaging and analytics platform using Tau-PET data from 931 participants and 1,570 scans, while CALMA remains the lead clinical catalyst. Recent filings show modest cash of $900,000, a working capital deficit of $366,000, and multiple convertible notes, plus an effective resale shelf covering 978,235 shares. Investors may watch CALMA progress, financing activity, and further biomarker validation as key signals.
Key Figures
Tau-PET participants:931 participantsTau-PET scans:1,570 scansInterim cohort size:n=26 patients+5 more
8 metrics
Tau-PET participants931 participantsF-AV-1451 Tau-PET imaging dataset from ADNI
Tau-PET scans1,570 scansF-AV-1451 Tau-PET imaging dataset from ADNI
Interim cohort sizen=26 patientsInitial CALMA Phase 2 cohort with agitation and sleep signals
Cash & equivalents$900,000Balance as of Dec 31, 2025 (Form 10-KT)
Working capital deficit$366,000Deficit as of Dec 31, 2025 (Form 10-KT)
Shares outstanding98,796,089 sharesCommon shares as of Mar 11, 2026 (Form 10-KT)
Ascendiant raises price target citing clinical progress and 2026 catalysts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent IGC news has mostly been positive on clinical and strategic fronts, with 3 aligned positive price moves and 2 instances where favorable updates (trial progress, new research authorization) were followed by short-term weakness.
Recent Company History
Over the past month, IGC has focused on advancing its Phase 2 CALMA trial for IGC-AD1, repeatedly reporting ~80% enrollment and adding a new clinical site in Dallas to support completion. The company also secured psilocybin research authorization in Colombia and highlighted an analyst price target increase on Apr 8. Today’s Tau-PET biomarker conference presentation fits this pattern of building an Alzheimer’s-focused platform around CALMA while expanding broader neurodegenerative research capabilities.
Key Terms
tau-pet, biomarker, shannon entropy, apoe4, +4 more
8 terms
tau-petmedical
"IGC Pharma to Present Tau-PET biomarker research at the 2026 Global Tau Conference"
tau-PET is a brain imaging scan that uses a tiny radioactive tracer to make visible accumulations of the protein tau, which build up in Alzheimer’s disease and other neurodegenerative disorders. For investors it matters because tau-PET can show whether a drug reaches and affects its intended target, help select patients most likely to benefit, and provide early evidence of effectiveness—much like a thermometer shows whether a treatment is working—which can materially affect trial outcomes, regulatory decisions and company value.
biomarkermedical
"Tau-PET biomarker research at the 2026 Global Tau Conference"
A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.
shannon entropytechnical
""Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression""
Shannon entropy is a numerical measure of how unpredictable or uncertain a set of outcomes is — for example, the spread of possible stock returns, trading signals, or pieces of news. Higher entropy means outcomes are more random and harder to predict, while lower entropy means patterns or a dominant outcome are more likely; investors use it like a thermometer for information: it helps judge how much useful signal exists versus noise when making decisions. An easy analogy is comparing a shuffled deck (high entropy) to a sorted deck (low entropy): the sorted deck gives more certainty about what comes next.
apoe4medical
"amyloid-positive APOE4 carriers"
APOE4 is a specific version of the APOE gene that increases the risk of developing Alzheimer’s disease and can influence how people respond to certain treatments. For investors, APOE4 matters because its prevalence in patient groups can shape clinical trial results, regulatory decisions and market size for therapies—like knowing a neighborhood’s weather pattern affects how many umbrellas a seller should stock.
braak-stagemedical
"tau distribution across Braak-stage regions appeared more focal or diffuse"
Braak stage is a neuropathology scale that describes how far a brain disease has progressed by mapping which brain areas are affected, like a road map that shows how damage spreads over time. For investors, it matters because clinical trial results, diagnosis accuracy and market demand for treatments or diagnostics often depend on disease stage—earlier stages may be easier to treat or detect, while later stages can mean smaller or different commercial opportunities.
neuroimaging initiativemedical
"scans obtained through the Alzheimer's Disease Neuroimaging Initiative (ADNI)"
A neuroimaging initiative is an organized program that develops and applies brain‑scanning methods (for example MRI or PET) to collect consistent imaging data for research, diagnosis or product development. For investors it matters because those efforts produce measurable evidence about how a treatment, device or condition affects the brain—like turning raw signals into maps and dashboards—helping reduce development risk, support regulatory claims, attract partners, or create sellable data assets.
neuroimagingmedical
"integrating advanced analytics, neuroimaging, and AI-driven approaches"
Neuroimaging is the set of medical techniques that create pictures or maps of the brain’s structure and activity, like using a camera or GPS to see what parts of the brain look like and how they behave. For investors, neuroimaging matters because it provides objective evidence used in clinical trials, product development and regulatory decisions, helping judge whether a therapy or device is likely to work, reduce risk, and reach the market.
phase 2 calma trialmedical
"advancing IGC-AD1 through the Phase 2 CALMA trial"
A Phase 2 CALMA trial is a mid-stage clinical study given the name “CALMA” that evaluates whether an experimental treatment has meaningful benefit and acceptable safety at specific doses in a target patient group. For investors, results act like a detailed road test: positive findings increase the chance the drug will progress to larger late-stage trials and eventual approval (boosting value), while negative or inconclusive results raise risk and can reduce a company’s prospects.
Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development.
POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C., and online.
The poster presentation, titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression in Amyloid-Positive APOE4 Carriers," evaluates whether Shannon entropy can serve as a quantitative measure of spatial heterogeneity in tau pathology, a key feature of Alzheimer's disease progression.
The analysis utilized F-AV-1451 Tau-PET imaging data from 931 participants and 1,570 scans obtained through the Alzheimer's Disease Neuroimaging Initiative (ADNI). The team assessed whether tau distribution across Braak-stage regions appeared more focal or diffuse and evaluated its relationship with cognition, amyloid status, APOE4 genotype, and longitudinal tau accumulation.
The findings suggest that among amyloid-positive participants with elevated tau burden, more focal tau spreading patterns were associated with worse cognitive and clinical outcomes and faster tau accumulation over time, particularly in APOE4 carriers. These results indicate that Shannon entropy may provide a concise imaging-derived measure of Tau-PET spatial heterogeneity with potential relevance for disease monitoring and patient stratification.
"The ability to better characterize heterogeneity in tau pathology may become increasingly important for Alzheimer's disease monitoring, patient stratification, and future therapeutic development," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "This research reflects IGC Pharma's broader strategy of integrating advanced analytics, neuroimaging, and AI-driven approaches to strengthen our Alzheimer's research platform while we continue advancing IGC-AD1 through the Phase 2 CALMA trial."
IGC Pharma believes that advanced biomarker characterization and computational imaging analytics may support the future design of Alzheimer's clinical studies, including approaches to stratify patients, monitor disease progression, and evaluate therapeutic response. These capabilities complement the Company's broader clinical development strategy in Alzheimer's disease, including its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.
The Global Tau Conference is an international scientific forum focused on tau-related neurodegenerative diseases, including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy. IGC Pharma's participation reflects the Company's continued engagement with the global Alzheimer's research community and its commitment to advancing scientific tools that may support future therapeutic innovation.
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements.
What Tau-PET biomarker research is IGC Pharma (IGC) presenting at the 2026 Global Tau Conference?
IGC Pharma is presenting research on using Shannon entropy to quantify Tau-PET spatial heterogeneity in Alzheimer’s disease. The analysis evaluates tau spreading patterns in 931 participants and links them with cognition, amyloid status, APOE4 genotype, and longitudinal tau accumulation.
How could IGC Pharma's Tau-PET Shannon entropy research impact Alzheimer’s disease monitoring for IGC stock investors?
The research suggests Shannon entropy may offer a concise imaging measure of Tau-PET spatial heterogeneity. According to IGC Pharma, this could help monitor disease progression, support patient stratification, and inform future therapeutic development strategies in Alzheimer’s clinical research.
What were the key findings from IGC Pharma’s Tau-PET analysis using ADNI data?
Among amyloid-positive participants with elevated tau, more focal tau spreading patterns were linked to worse cognitive and clinical outcomes. According to IGC Pharma, these patterns were also associated with faster tau accumulation over time, particularly in APOE4 carriers.
How does IGC Pharma’s Tau-PET biomarker work relate to its IGC-AD1 Phase 2 CALMA trial?
IGC Pharma states that advanced biomarker characterization and computational imaging analytics are part of its broader Alzheimer’s strategy. These tools are intended to complement the ongoing Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.
Why is IGC Pharma’s participation in the 2026 Global Tau Conference important for Alzheimer’s research?
Participation highlights IGC Pharma’s engagement with the global tau research community and focus on Alzheimer’s disease. According to the company, presenting Tau-PET entropy work supports development of scientific tools for patient stratification, disease monitoring, and assessing therapeutic response in future studies.
